Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Buffers and Standards
  4. Chromatography Standards
  5. Drug Standards
  6. 111012232

Nimodipine Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™

Catalog No. 111012232
Click to view available options
Quantity:
1 g

Description

Nimodipine is a well-known calcium antagonist and is a moderate cerebral vasodilator, in addition to being an inhibitor of cerebrovascular reactivity. It is suggested to be cytoprotective by causing a decrease in the influx of calcium into the nerve cells. It is accepted for use in the management of delayed ischaemic dysfunction and is commonlly used in the studies of brain function impairment and dementia in old age.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
TRUSTED_SUSTAINABILITY

Specifications

CAS 66085-59-4
Purity Grade Notes These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.
Physical Form Neat
Linear Formula C21H26N2O7
MDL Number MFCD00153848
Synonym Nimodipine; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Type Certified Reference Material
Quantity 1 g
Formula Weight 418.44
Grade Certified Reference Material
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.